Delayed Parsabiv now needs to be a $3-$5B drug to save Amgen

Because.....

Amgen's new drugs suck

1. Kyprolis ain't growing enough....stalled US sales for the last 2 years
2. Imlygic ain't selling
3. Corlanor is a dog with fleas
4. Repatha now dreams of $M dollar sales not $B
5. Blincyto - Limited sales cuz no one wants continuous infusion
6. Erenumab - Teva, Lilly and Adler breathing down your throats and you have to share whatever is left with Novartis

Amgen's old drugs

1. Enbrel - Each day Humira kills you in both rheum and derm. Orals are coming to RA
2. Neulasta/ Neupogen - Biosimilars are knocking. Onpro can only stave off so much
3. Aranesp/Epogen - Drugs from the 1980's.....you are lucky to still be selling at all
4. Vectibix - Amgen's failure forray into therapeutic oncology

Amgen's semi-old drugs

1. Prolia/Xgeva - You never lived up to your $5-6B potential so Jim Daley was fired. But at $1.5B+ after 7 years you are solid and sadly the best driver of growth despite being limited. You are at best a B player, solid but cannot hold the company on your back
2. Sensipar - Same thing but you gonna be generic soon.....

The question is:

1. When is Trump letting Amgen bring back $30B in overseas cash
2. Who will Amgen overspend on in desperation
3. Or will Amgen be part of a mega-merger where Bob gets a golden parachute
4. But either route - Expect layoff packages!